ReviewJournal of neurology2016
Cardiovascular adverse effects of phenytoin.
Review in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 67 citations in OpenAlex.
- Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus.Indian journal of pediatrics · 2020Trial
- Seizures Secondary to Aconitum Plant Poisoning: a case report.Journal of medical case reports · 2026Article
- Cardiovascular Effects of Antiseizure Medications for Epilepsy.CNS drugs · 2025Review
- Antiseizure medications and their differing effects on cardiovascular risk.Epilepsy & behavior reports · 2025Review
- Associations of medical outcomes with substances involved in suicide attempt cases age 50 and older reported to U.S. Poison Centers, 2016-2023.Frontiers in public health · 2025Observational
- A narrative review and new insights into the protective effects of taurine against drug side effects.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Black-Box Warnings of Antiseizure Medications: What is Inside the Box?Pharmaceutical medicine · 2023Review
- Article
- Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.Clinical and translational science · 2022Article
- Evaluation of Cardiovascular Concerns of Intravenous Lacosamide Therapy in Epilepsy Patients.Frontiers in neurology · 2022Article
- Phenytoin as treatment for bidirectional ventricular tachycardia in a patient with anterior myocardial infarction and digoxin toxicity.Archivos de cardiologia de Mexico · 2022Article
- Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.Aging and disease · 2021Review
- Effects of long-term anti-seizure medication monotherapy on all-cause death in patients with post-stroke epilepsy: a nationwide population-based study in Taiwan.BMC neurology · 2021Article
- A 'shark'-masked electrocardiogram: case report of a Tako-Tsubo syndrome.European heart journal. Case reports · 2021Article
- Effect of Lamotrigine on Ouabain-Induced Arrhythmia in Isolated Atria of Guinea Pigs.Medical journal of the Islamic Republic of Iran · 2021Article
- 36-year-old Male with Syncope.Clinical practice and cases in emergency medicine · 2020Article
- Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsis.BMJ case reports · 2020Article
- Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status Epilepticus: Propensity Score Matching Analysis Using a Nationwide Inpatient Database.Frontiers in neurology · 2020Article
- Blood Pressure in Seizures and Epilepsy.Frontiers in neurology · 2019Review
- New mechanisms of phenytoin in calcium homeostasis: competitive inhibition of CD38 in hippocampal cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phenytoin is an established drug in the treatment of acute repetitive seizures and status epilepticus. One of its main advantages over benzodiazepines is the less sedative effect. However, the possibility of cardiovascular adverse effects with the intravenous use of phenytoin cause a reluctance to its usage, and this has lead to a search for safer anticonvulsant drugs. In this study, we aimed to review the studies which evaluated the safety of phenytoin with respect to cardiovascular adverse effects. The original clinical trials and case reports listed in PUBMED in English language between the years of 1946-2014 were evaluated. As the key words, "phenytoin, diphenylhydantoin, epilepsy, seizure, cardiac toxicity, asystole, arrhythmia, respiratory arrest, hypotension, death" were used. Thirty-two clinical trials and ten case reports were identified. In the case reports, a rapid infusion rate (>50 mg/min) of phenytoin appeared as the major cause of increased mortality. In contrast, no serious cardiovascular adverse effects leading to death were met in the clinical trials which applied the recommended infusion rate and dosages. An infusion rate of 50 mg/min was reported to be safe for young patients. For old patients and patients with a cardiovascular co-morbidity, a slower infusion rate was recommended with a careful follow-up of heart rhythm and blood pressure. No cardiovascular adverse effect was reported in oral phenytoin overdoses except one case with a very high serum phenytoin level and hypoalbuminemia. Phenytoin is an effective and well tolerated drug in the treatment of epilepsy. Intravenous phenytoin is safe when given at recommended infusion rates and doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.